Studies have shown that the anti-tumor action of CTLA-4 blockers depends on different bacteriophage types (124–126), and that CTLA-4 antibody treatment of melanoma patients favors the growth of Bifidobacterium fragilis, which has anti-cancer properties (112). This evidence concerns the gene CTLA4 and melanoma.